BETA
Your AI-Trained Oncology Knowledge Connection!
EP. 1: The Status of CAR T in Hematologic Malignancies
EP. 2: Practicality of CAR T Therapy
EP. 3: Managing CAR T-Cell Therapy Toxicity
EP. 4: Mechanisms of Resistance for CAR T Therapy
EP. 5: The Promise of CAR T-Cell Therapy for ALL
EP. 6: Tisagenlecleucel for Relapsed/Refractory ALL
EP. 7: Clinical Data Behind CAR T-Cell Therapies in ALL
EP. 8: Need for Salvage Therapies in R/R NHL
EP. 9: FDA Approval for Axi-Cel in NHL
EP. 10: Clinical Data for Axi-Cel in Lymphoma
EP. 11: Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma
EP. 12: JCAR017 for B-Cell NHL
EP. 13: The Use of CTL019 in Lymphoma
EP. 14: Allogeneic CAR T-Cell Approaches for NHL
EP. 15: BCMA-Targeted CAR T-Cell Therapy for Myeloma
EP. 16: Potential for CAR T-Cell Therapy for R/R AML
EP. 17: Evaluating CAR T-Cell Therapy Use
EP. 18: Cost Effectiveness and Future of CAR T Therapy
UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer
Oncology Experts Preview Top Abstracts From AUA 2025
Future of Bispecifics and CAR T in R/R MM
Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM